GIANNINI, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 1.289
EU - Europa 1.257
AS - Asia 134
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.684
Nazione #
US - Stati Uniti d'America 1.286
GB - Regno Unito 419
IE - Irlanda 239
IT - Italia 233
SE - Svezia 125
CN - Cina 88
FR - Francia 67
UA - Ucraina 56
DE - Germania 38
ES - Italia 28
FI - Finlandia 20
IN - India 15
TR - Turchia 14
BE - Belgio 13
IR - Iran 8
GR - Grecia 7
RU - Federazione Russa 4
SA - Arabia Saudita 4
NL - Olanda 3
PL - Polonia 3
CA - Canada 2
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
BR - Brasile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EU - Europa 1
JP - Giappone 1
MX - Messico 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 2.684
Città #
Southend 398
Dublin 238
Fairfield 234
Chandler 147
Ashburn 95
Woodbridge 91
Cambridge 80
Seattle 80
Houston 76
Ann Arbor 68
Wilmington 67
Siena 62
Jacksonville 49
Beijing 40
Princeton 39
New York 32
Málaga 21
Rome 21
Helsinki 19
San Mateo 16
Dearborn 14
Brussels 13
Izmir 11
Nanjing 11
San Diego 11
Fremont 10
Boardman 8
Redwood City 8
Milan 6
Cagliari 4
Florence 4
Jinan 4
London 4
Nanchang 4
Riyadh 4
Roccagorga 4
Salamanca 4
Shanghai 4
Tianjin 4
Fort Worth 3
Hebei 3
Kilburn 3
Naples 3
Norwalk 3
Perugia 3
Amsterdam 2
Andover 2
Azzano San Paolo 2
Bathinda 2
Brescia 2
Changsha 2
Chongqing 2
Esslingen am Neckar 2
Foggia 2
Grosseto 2
Islington 2
Jiaxing 2
Kocaeli 2
Kunming 2
Leawood 2
Marano Di Napoli 2
Mumbai 2
Ningbo 2
Oklahoma City 2
Paris 2
Redmond 2
Reggio Emilia 2
Saint-Fons 2
San Francisco 2
Strigno 2
Toronto 2
Turin 2
Verona 2
Wandsworth 2
Zanjan 2
Adana 1
Alcorcón 1
Alezio 1
Alghero 1
Antea 1
Avellino 1
Bangalore 1
Boston 1
Bratislava 1
Buffalo 1
Canberra 1
Castelvetrano 1
Chicago 1
Clearwater 1
Cosenza 1
Council Bluffs 1
Dhaka 1
Dresden 1
Frankfurt am Main 1
Garching 1
Guangzhou 1
Haikou 1
Hangzhou 1
Heraklion 1
Hounslow 1
Totale 2.108
Nome #
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 209
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 192
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 184
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 180
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 157
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 152
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 148
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 145
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 144
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 136
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 135
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 119
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. 118
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 112
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 111
HIV drug discovery and resistance testing through cell based assays 107
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 103
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 100
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 83
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 56
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 39
null 32
Totale 2.762
Categoria #
all - tutte 9.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.142


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201948 0 0 0 0 0 0 0 0 0 0 0 48
2019/2020607 36 30 80 66 37 49 55 54 47 71 33 49
2020/2021580 28 38 13 56 67 84 62 75 48 61 16 32
2021/2022482 26 59 35 51 34 28 31 28 28 42 41 79
2022/2023464 29 76 57 52 30 82 24 31 32 27 18 6
2023/2024367 14 6 35 35 4 109 139 15 1 4 5 0
Totale 2.762